Melinta Therapeutics has been granted a patent for a method to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in overweight or obese patients. The method involves administering 300 mg of delafloxacin intravenously twice daily. This approach addresses the specific needs of a significant portion of the U.S. adult population. GlobalData’s report on Melinta Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Melinta Therapeutics, NSAID cancer drugs was a key innovation area identified from patents. Melinta Therapeutics's grant share as of June 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Treating infections in obese patients with delafloxacin
The granted patent US12036219B2 outlines a specific method for treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in overweight or obese patients. The method involves the intravenous administration of 300 mg of delafloxacin, or its pharmaceutically acceptable salt, ester, or prodrug, twice daily. This treatment is particularly targeted at patients who are classified as overweight or obese, defined by a body mass index (BMI) of 25 or higher. The claims emphasize the importance of this treatment regimen for patients with varying degrees of obesity, as indicated by the subsequent claims that specify BMI thresholds of 30, 35, and 40.
The patent delineates a clear framework for the administration of delafloxacin, focusing on its efficacy in a specific patient demographic that may be at higher risk for complications from ABSSSI. By establishing a method tailored to overweight and obese individuals, the patent addresses a significant healthcare need, potentially improving treatment outcomes in this population. The claims collectively highlight the method's applicability across a range of obesity classifications, thereby underscoring the relevance of BMI in the therapeutic approach to managing ABSSSI.
To know more about GlobalData’s detailed insights on Melinta Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
